Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older (or above the legal age of consent in their country) at the time of signing the consent form.
• People with a confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (a specific type of lung cancer) that has either spread to other parts of the body or is not suitable for definitive treatment (Stage III or IV).
• People whose lung cancer tumour has a specific genetic change (called a HER2 mutation in the tyrosine kinase domain), confirmed by an approved laboratory test on tumour tissue.
• People who have not previously received systemic (whole-body) treatment for advanced or metastatic disease, and have not previously been treated with therapies specifically targeting a HER2 mutation. People who received treatment before or after surgery may still be considered, provided that treatment finished at least 12 months before the start of the screening period.
• People whose treating doctor determines they are medically suitable to receive a specific combination of chemotherapy (cisplatin or carboplatin with pemetrexed) plus a drug called pembrolizumab, in line with official prescribing guidelines.

Who may not be able to join:

• People with a history of another cancer, unless they received potentially curative treatment with no sign of the cancer returning for at least 5 years. Exceptions apply for certain cancer types if curatively treated or under surveillance: early-stage cervical, breast, or skin cancers; certain superficial bladder cancers; limited-stage prostate cancer; or basal or squamous cell skin cancers.
• People whose tumour has a different genetic change for which an approved targeted treatment already exists (other than the specific HER2 mutation this trial is studying).
• People who cannot stop taking ongoing oral or injected corticosteroid (steroid) medicines. People using inhalers, bronchodilators, or occasional local steroid injections would not be excluded. People using low-dose steroids to manage a hormone deficiency (such as adrenal or pituitary insufficiency) may still be considered, provided the dose has been stable for more than 4 weeks before the planned trial start.
• People who already have moderate or severe nerve damage (called peripheral neuropathy, graded 2 or higher) before joining the trial.
• People who have had a severe allergic reaction to a type of medicine called a monoclonal antibody in the past.
• People who received radiation therapy to any part of the body outside the brain within 21 days before the planned trial start, or who are still experiencing side effects from prior radiation treatment.

Important: Always verify eligibility with the trial site directly before applying.